Keyword: Rubius Therapeutics

Rubius Therapeutics

Rubius is developing off-the-shelf red-cell therapeutics its president Torben Straight Nissen thinks will be “an improved and superior cellular therapy over the CAR-Ts.” Buoyed by a $120 million round, the Flagship Pioneering-backed biotech is working on a pipeline that extends beyond cancer.

FierceBiotech's 2017 Fierce 15

The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the brightest teams, and we want to see the promise that they hold in their hands has a genuine chance of being the Next Big Thing. Here are this year's standouts.